RO-6870810

DB15151InvestigationalSmall molecule

RO-6870810 is under investigation in clinical trial NCT02308761 (A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome).

Formula / weight: C₂₇H₃₄ClN₇OS · 540.13 g/mol (avg)
Also known as: 2-[(4S)-6-(4-chlorophenyl)-1,7,8-trimethylthiophenol[3,2-f]1,2,4-triazolo[4,3-a]1,4-diazepin-4-yl]-N-[3-(4-methylpiperazinyl)propyl]acetamide · 6H-THIENO(3,2-F)(1,2,4)TRIAZOLO(4,3-A)(1,4)DIAZEPINE-6-ACETAMIDE, 4-(4-CHLOROPHENYL)-2,3,9-TRIMETHYL-N-(3-(4-METHYL-1-PIPERAZINYL)PROPYL)-, (6S)- · BET INHIBITOR RO6870810 · BET INHIBITOR TEN-010
Code names: JQ-35, (S)- · RO-6870810

Resolves to

Compound

UNIITA3QN7788DCAS1349719-98-7ChEMBLCHEMBL4297423

Structure

InChIKeyPKQXLRYFPSZKDU-QFIPXVFZSA-NSMILESCN1CCN(CCCNC(=O)C[C@@H]2N=C(C3=C(SC(C)=C3C)N3C(C)=NN=C23)C2=CC=C(Cl)C=C2)CC1

What you can answer from here — as of September 13, 2026

5Clinical trialsPhase, status and sponsor resolved per trial

Which companies are running trials of RO-6870810, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account